Nicorandil mitigates arsenic trioxide‐induced lung injury via modulating vital signalling pathways SIRT1/PGC‐1α/TFAM, JAK1/STAT3, and miRNA‐132 expression
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16414 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Basel A Abdel-Wahab und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Najran University, Najran, Saudi Arabia. Hauptthemen laut MEDLINE: Nicorandil, STAT3 Transcription Factor, Sirtuin 1, Signal Transduction. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: Ministry of Education and Deanship of Scientific Research at Najran University, Ministry of Education and the Deanship of Scientific Research at Najran University.
Abstract (Originalsprache)
Background and Purpose Nicorandil, a selective opener of potassium channels, used to treat angina, has drawn attention for its potential in mitigating lung injury, positioning it as a promising therapeutic approach to treat drug‐induced lung toxicity. This study aimed to explore the protective role of nicorandil in arsenic trioxide (ATO)‐induced lung injury and to elucidate the underlying mechanistic pathways. Experimental Approach We assessed the effects of nicorandil (15 mg·kg −1 , p.o.) in a rat model of pulmonary injury induced by ATO (5 mg·kg −1 , i.p.). The assessment included oxidative stress biomarkers, inflammatory cytokine levels, and other biomarkers, including sirtuin‐1, sirtuin‐3, STAT3, TFAM, and JAK in lung tissue. Histological examination using H&E staining and molecular investigations using western blotting and PCR techniques were conducted. Key Results In our model of lung injury, treatment with nicorandil ameliorated pathological changes as seen with H&E staining, reduced tissue levels of toxicity markers, and exerted significant antioxidant and anti‐inflammatory actions. On a molecular level, treatment with nicorandil down‐regulated JAK, STAT3, PPARγ, Nrf2, VEGF, p53, and micro‐RNA 132 while up‐regulating Sirt1, 3, TFAM, AMPK, and ERR‐α in lung tissue. Conclusions and Implications The results presented here show nicorandil as a significant agent in attenuating lung injury induced by ATO in a rodent model. Nonetheless, further clinical studies are warranted to strengthen these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Najran University, Najran, Saudi Arabia.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern University of Technology, and Information, Cairo, Egypt.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, Egypt.
ORCID-Profile: Ehab A M El-Shoura
Förderung
- Ministry of Education and Deanship of Scientific Research at Najran University
- Ministry of Education and the Deanship of Scientific Research at Najran University
Zitieren
APA
Abdel-Wahab, B. A., Zafaar, D., Habeeb, M. S., & El-Shoura, E. A. M. (2024). Nicorandil mitigates arsenic trioxide‐induced lung injury via modulating vital signalling pathways SIRT1/PGC‐1α/TFAM, JAK1/STAT3, and miRNA‐132 expression. British Journal of Pharmacology. https://doi.org/10.1111/bph.16414
Vancouver
Abdel-Wahab BA, Zafaar D, Habeeb MS, El-Shoura EAM. Nicorandil mitigates arsenic trioxide‐induced lung injury via modulating vital signalling pathways SIRT1/PGC‐1α/TFAM, JAK1/STAT3, and miRNA‐132 expression. British Journal of Pharmacology. 2024. doi:10.1111/bph.16414
BibTeX
@article{AbdelWahab2024,
author = {Abdel-Wahab, Basel A and Zafaar, Dalia and Habeeb, Mohammed Shafiuddin and El-Shoura, Ehab A M},
title = {Nicorandil mitigates arsenic trioxide‐induced lung injury via modulating vital signalling pathways SIRT1/PGC‐1α/TFAM, JAK1/STAT3, and miRNA‐132 expression},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16414}
}
EUVIMED